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1041-119 Age-Dependent  Modu la t ion  of  Vu lnerabi l i ty  to  Nicotine 
for Inducible Atrial Fibrillation 
Hideki Havashi. Charles Wang, Chikaya Omichi, Yasushi Miyauchi, William J. Mandel, 
Peng-Sheng Chen, Hrayr S. Karagueuzian, Cedars-Sinai Medical Center and UCLA 
School of Medicine, Los Angeles, California. 
BACKGROUND Nicotine (N) has been implicated as a potential cause of a broad spec- 
trum of cardiac arrhythmias including atrial fibrillation (AF). The factors responsible for 
N's vadable influence on AF vulnerability remain undefined. We hypothesized that aging 
is one factor that modulates AF vulnerability to N. METHODS Twelve male rats (Fisher- 
344) were grouped into young (2-3 months, N=6) and old (22-24 months, N--6). The iso- 
lated heads were perfused via the aorta and superfused with oxygenated Tyrode's at 
37°C. Atrial effective refractory period (ERP), interatrial conduction time (CT) and AF vul- 
nerability tested by burst pacing were determined before and after 10-100 ng/ml N pedu- 
sion. [The arterial blood levels of N in smokers is between 30-85 ng/ml]. The epicardial 
surface of the atria was optically mapped using CCD camera. RESULTS At baseline, CT 
was significantly greater in the old than in the young rats (52±32 vs. 25±5 ms, P<0.05), 
however, there was no significant difference in the ERP between the two groups 
(19.2±4.8 vs. t9.3±7.6 ms). Burst pacing induced AF in 5 of the 6 old rats. However, no 
AF could be induced in any of the 6 young rats. N increased interatrial CT and ERP in a 
concentration-dependent manner that was significantly (P<0.05) higher in the old than in 
the young rats (90±34 ms vs. 35±9 ms and 24±4 ms vs. 27±3 ms respectively dudng 80 
ng/ml N perfusion). N at 10-30 ng/ml prevented AF induction in the old rats, however 
atrial tachycardia (AT) could still be induced in 5/6 old rats. N at 50 ng/ml and above pre- 
vented AF and AT induction in the old rats. In contrast however N at 10-100 ng/ml signif- 
icantly (P<0.01) increased AF (N=3) and AT (N=3) induction in the young rats. Optical 
mapping showed the presence of 2-3 independent wave fronts during AF but only one 
large periodic wave front during AT. Old rats had significantly (P<0.05) greater interstitial 
atrial fibrosis compared to young rats (1.72±0.81 vs. 0.38±0.45%). CONCLUSION The 
mechanism of N-induced modulation of AF vulnerability is compatible with changes in 
interatriat CT and ERP. In atria with less than a critical increase in the CT/ERP (young 
rats at baseline) or excessive increase in CT/ERP (aged atria exposed to N >50 ng/ml) 
AF/AT can not be induced. 
1041-120 Human Beta3-adrenoreceptora  coup le  to the KvLQT1/ 
minK Potassium Channels via Protein Klnase A - 
Protein Kinase C Cross-talk 
Johann Kiehn, Wei Zhang, Katja Roeckl, Christoph Karle, Sven Kathoefer, Medical 
University Hospital Heidelberg, Heidelberg, Germany. 
Excessive stimulation of adrenergic beta-receptors in heart has been linked to the 
occurance of life threatening arrhythmias in conditions like Long QT-Syndrome and 
ischemic or dilated cardiomyopathy. In the pathogenesis of arrhythmias one crucial ele- 
ment is the slow component of the delayed rectifier potassium current (IKs), which trig- 
gers and pedorms repolarzation of the cardiac action potential IKs is known to be 
coupled to the beta-adrenergic system in cardiomyocytes, but the type of beta-adrener- 
gic receptor and the signal transduction cascade, which regulates this current under 
physiological and pathophysiological conditions, are unknown. We investigated the func- 
tional coupling of the beta-adranergic system to IKs by expressing hetarologously its 
molecular components, the KvLQT1/minK potassium channel together with human beta 
receptors, in Xenopus Oozytes. Membrane currents were measured with the double 
electrode voltage-clamp technique. We found that human beta3-adrenergic receptors 
couple functionally to the KvLOT1/minK potassium channel. Moreover we investigated 
the signal transduction pathway and identified that Gs-protains, adenylatecyclase and 
cAMP are beeing involved. Further downstream in the signal transduction cascade pro- 
tein kinase A activates protein kinase C via cross-talk and finally protein kinase C phos- 
phorylatas the KvLQT1 protein. The latter has been shown in site-directed mutagenesis 
experiments, where the putative protein kinase C phosphorylation sites have been 
destroyed in the KvLQTl-protein. The knowledge about the coupling and the signal 
transduction cascade between adrenergic beta-receptors and the KvLQT1/minK potas- 
sium channel reveals new aspects about the genesis and therapy of cardiac arrhythmias. 
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1042-112 Prevention of Atrial Fibrillation Using Antlarrhythmic 
Drugs Postcardioveraion of New Onset Atrial 
Fibr i l lat ion 
Huaoui Li, Roger Riedel, Brad Oldemeyer, Rich Wurdman, Karen Rovang, Tom Hee, The 
Cardiac Center of Creighton Universi~ Omaha, Nebraska. 
The use of antiarrhythmic drugs to prevent recurrence of atrial fibrillation (AF) is often 
avoided in patients presenting with new onset AF, especially those who spontaneously 
convert o normal sinus rhythm. It is uncertain whether patients presenting with sustained 
AF (new onset) requiring DC cardioversion should be managed similarly. Methods: Med- 
ical chart review identified 150 consecutive patients who presented with new onset AF 
(sustained AF>48 hours) and underwent DC cardioversion in our center between 1/1997 
and 12/2000. Patients with reversible etiologies or previous paroxysmal AF were 
excluded. Patients were divided into two groups, those placed on class I or III antiarrhyth- 
mic drugs post cardioversion (Group I, n=51) and those not placed on any antiarrhythmic 
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drugs (Group II, n=99). Patients were followed up to 48 months. Results: There were no 
significant differences in gender distribution, mean age, underlying cardiovascular dis- 
ease, left ventricular function, left atdal diameter and the use of beta-blockers between 
the two groups. AF recurrence rate was significantly higher in Group II than Group I 
patients (p<0.05), with only 25% of the Group II patients remaining in sinus rhythm at 1 
year (Figure). 
Concluelon: The data suggest, in the absence of a reversible etiology, an antiarrhythmic 
drug should be initiated for prevention of AF following DC cardioversion in patients pre- 
senting with new onset AF. 
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1042-113 Az iml l lde  Reduces Symptom Burden at the Time of 
Arrhythmia Recurrence in Patients With Atrial 
Fibrillation 
Stuart J. Connollv. Marcia Schulte, Edward L Pdtchett, Richard L. Page, Stephen R. 
Marcello, Daniel Schnell, William E. Wilkinson, McMaster University, Hamilton, Ontario, 
Canada. 
Azimilide is a novel Class Iti antiarrhythmic agent with favourable efficacy and safety pro- 
files. Meta-analysis of 4 randomized placebo-controlled trials has shown that doses of 
both 100 and 125 mg/day prolong time to recurrence of atrial fibrillation/flutter (AF). In 
addition to measuring time to recurrence, assessing total symptom burden is an impor- 
tant outcome in trials evaluating treatments for AF. Therefore a 6 item Symnptom Burden 
Index (SBI) was measured at the time of arrhythmia recurrence documented by trans- 
telephonic monitodng in patients with AF, randomized to either azimilide (125 mg/day) or 
placebo in 2 separate trials, RESULTS: The 125 rag/day dose of azimilide significantly 
reduced the SBI compared to placebo in both trials. The heart rate measured at the time 
of arrhythmia recurrence was not significantly different between azimilide (125 mg/day) 
and placebo in either study. CONCLUSION: Azimilide reduces the number of symptoms 
reported at the time of recurrence of arrhythmia in patients with AE This effect is not 
mediated by a significant change in heart rate at the time of arrhythmia recurrence. 
Symptom Burden st Time of Documented Arrhythmia Recurrence 
tn 2 Randomized Trials of Azlmlllde 
Symptom Burden 
Index 
Study 1 Study 2 
Placebo (N=64) Azimilide (N=43) Placebo (N=129) Azimilide (N=118) 
0 or 1 41% 67% 32% 45% 
2 38% 9% 22% 25% 
3 or more 22% 23% 47% 30% 
P value 0.04 0.004 
The Symptom Burden Index (SBI) gives I point for self-reported symptoms in each of 6 
categories: palpitation, fatigue, dyspnea, dizziness, chest pain, sweating. The SBI 
range is 0-6, with 6 being the most burdensome. The P value was calculated using SBI 
values 0-6. 
1042-114 Role of  Verapamil  in Atr ia l  F ibr i l lat ion:  Effect on Trigger 
or  on Subatrate? Data From the VeRAF Study 
Giovanni L. Botto. Giuseppina Belotti, Antonio Cirb, Vigitio Ziacchi, Massimo Romanb, 
Massimo Pals, Antonio Sagone, Antonino Piti, Antonello Vincenti, Giampaolo Gelmini, 
on behalf of The VeRAF Study Group, StAnna Hospital, Como, Italy, 
Background. Several animal studies suggested the possible role of verapamil (VER) in 
preventing tachycardia-induced atdal electrical remodeling. It's still a matter of debate if 
this is a reality in humans, and, if yes, how can VER act in this field. 
Methods. We analized 156 patients (pts), mean age 68±9 years, NYHA functional class 
I-II, included in the VeRAF-Study, randomized to standard therapy (STD) (N=84) or addi- 
tional VER (N=72), 1 month before and after successful electrical cardioversion (EC) for 
persistent atrial fibrillation (AF) (mean duration 166¢105 days). No antiarrhythmic drugs 
were given. The incidence of premature atrial complexes(PACe) and their shortest P-P' 
coupling intewal (P-P'min) during 30" after sinus ryhtm (SR) resumption, were evaluated. 
Results. immediate (within 1 hour) recurrence of AF (IRAF) occurred in 21 pts and eady 
(within 7 days) recurrence (ERAF) in 49 pts. SR persisted 7 days after EC (SR) in 86 pts. 
The main results are reported in table 1 
P-P'min was longer in VER compared to STD (507±107 msec vs 382±157 msec, 
p<0.0001), while no differences were found concerning PACs between the two treat- 
ments (7±8 vs 6±5). 
Conclusion. A higher number of PACs together a shorter P-P'min caracterized IRAF. Fur- 
